In other words, the price has increased by $0.00 from its previous closing price. On the day, 2737352 shares were traded.
Ratios:
For a better understanding of OCUL, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.96 and its Current Ratio is at 4.03. In the meantime, Its Debt-to-Equity ratio is 10.58 whereas as Long-Term Debt/Eq ratio is at 10.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on February 09, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On April 21, 2023, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $18.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 26 when SUMMER ROAD LLC bought 930,851 shares for $7.52 per share. The transaction valued at 7,000,000 led to the insider holds 8,591,401 shares of the business.
Mattessich Antony C. sold 18,338 shares of OCUL for $90,773 on Jan 31. The President and CEO now owns 427,943 shares after completing the transaction at $4.95 per share. On Jan 31, another insider, Ozden Rabia Gurses, who serves as the Chief Medical Officer of the company, sold 7,764 shares for $4.95 each. As a result, the insider received 38,432 and left with 92,767 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 1.14B and an Enterprise Value of 1.11B. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.90 while its Price-to-Book (P/B) ratio in mrq is 100.11. Its current Enterprise Value per Revenue stands at 19.20 whereas that against EBITDA is -19.97.
Stock Price History:
Over the past 52 weeks, OCUL has reached a high of $10.55, while it has fallen to a 52-week low of $2.00. The 50-Day Moving Average of the stock is 5.11, while the 200-Day Moving Average is calculated to be 4.35.
Shares Statistics:
Over the past 3-months, OCUL traded about 1.79M shares per day on average, while over the past 10 days, OCUL traded about 3.37M shares per day. A total of 110.22M shares are outstanding, with a floating share count of 97.68M. Insiders hold about 11.38% of the company’s shares, while institutions hold 59.92% stake in the company. Shares short for OCUL as of Jan 31, 2024 were 3.96M with a Short Ratio of 2.21, compared to 4.38M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 3.45% and a Short% of Float of 3.66%.
Earnings Estimates
Current recommendations for the stock of the company come from 8 analysts. On average, analysts expect EPS of -$0.3 for the current quarter, with a high estimate of -$0.19 and a low estimate of -$0.54, while EPS last year was -$0.24. The consensus estimate for the next quarter is -$0.21, with high estimates of -$0.17 and low estimates of -$0.27.
Analysts are recommending an EPS of between -$0.83 and -$1.2 for the fiscal current year, implying an average EPS of -$0.99. EPS for the following year is -$0.92, with 8 analysts recommending between -$0.62 and -$1.25.
Revenue Estimates
8 analysts predict $15.71M in revenue for the current quarter. It ranges from a high estimate of $16.4M to a low estimate of $14.71M. As of the current estimate, Ocular Therapeutix Inc’s year-ago sales were $14.08M, an estimated increase of 11.60% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $17.29M, an increase of 29.30% over than the figure of $11.60% in the same quarter last year. There is a high estimate of $22.28M for the next quarter, whereas the lowest estimate is $15.14M.
A total of 8 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $60.2M, while the lowest revenue estimate was $58.3M, resulting in an average revenue estimate of $59.42M. In the same quarter a year ago, actual revenue was $51.49M, up 15.40% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $73.76M in the next fiscal year. The high estimate is $89.13M and the low estimate is $69.43M. The average revenue growth estimate for next year is up 24.10% from the average revenue estimate for this year.
